Key result
Antineoplastic agents, including older chemotherapies and newer targeted or biologic drugs, are associated with short- and long-term cardiovascular toxicity in cancer patients.
Why the study?
What are the cardiovascular toxicities associated with specific antineoplastic agents in patients with malignancies?
What are the cardiovascular toxicities associated with specific antineoplastic agents in patients with malignancies?
This review highlights the importance of recognizing and managing the short- and long-term cardiovascular toxicities associated with both traditional and newer cancer therapies.
No takes yet. Share an insight, caveat, or question.
Supports cardio-oncology monitoring in cancer patients; leaves open optimal prevention and risk-stratification strategies.
COMBES et al. (2011) conducted a review in Cancer and chemotherapy-induced cardiotoxicity. Antineoplastic agents was evaluated. Antineoplastic agents, including older chemotherapies and newer targeted or biologic drugs, are associated with short- and long-term cardiovascular toxicity in cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: